February 22, 1985

Benefits of Danazol Treatment in Patients With Hemophilia A (Classic Hemophilia)

Author Affiliations

From the Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md (Drs Gralnick and Rick); and Laboratoire d'Hemostase, Hospital Cochin, Paris (Drs Maisonneuve and Sultan).

JAMA. 1985;253(8):1151-1153. doi:10.1001/jama.1985.03350320075020

Danazol, an attenuated androgen, was given intermittently to three patients with hemophilia A. The rise in factor VIII activity with danazol treatment was associated with a fivefold decrease in hemorrhagic episodes and plasma concentrate product utilization when compared with similar periods without the drug. Four other patients with moderate hemophilia A who received danazol for 14 days had an increase of 400% to 850% in their factor VIII levels. Of four patients without detectable levels of factor VIII who were treated with danazol, two had elevations of the factor VIII level, to 3% and 4%, respectively. Danazol appears to be an effective treatment for patients with hemophilia A.

(JAMA 1985;253:1151-1153)